Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients
WEDNESDAY, Sept. 12, 2018 -- Among pediatric patients with relapsing multiple sclerosis, fingolimod is associated with a lower rate of relapse but a higher rate of serious adverse events than interferon beta-1a, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 12, 2018 Category: Pharmaceuticals Source Type: news

New Drug Fingolimod (Gilenya) Could Help Kids With MS
WEDNESDAY, Sept. 12, 2018 -- Researchers say the first drug for children with multiple sclerosis vastly outperformed another common MS medication in a new clinical trial. Fingolimod (Gilenya) reduced relapse rates by 82 percent in patients aged 10... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 12, 2018 Category: General Medicine Source Type: news

Natalizumab cost effective versus fingolimod for RRMS
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Expands Use of MS Drug to Include Children
MONDAY, May 14, 2018 -- The U.S. Food and Drug Administration has expanded its approval of the multiple sclerosis drug Gilenya (fingolimod) to include children aged 10 and older. It's the first multiple sclerosis drug approved for children, the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 14, 2018 Category: Pharmaceuticals Source Type: news

Use of MS Drug, Gilenya (Fingolimod), Expanded to Include Children
MONDAY, May 14, 2018 -- The U.S. Food and Drug Administration has expanded its approval of the multiple sclerosis drug Gilenya (fingolimod) to include children aged 10 and older. It's the first multiple sclerosis drug approved for children, the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 14, 2018 Category: General Medicine Source Type: news

FDA Okays Fingolimod (Gilenya), First Treatment for Pediatric MS FDA Okays Fingolimod (Gilenya), First Treatment for Pediatric MS
The FDA has expanded approval of the oral agent fingolimod from treatment for adults to treatment for children and adolescents aged 10 and up with multiple sclerosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 11, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA Expands Approval of Gilenya (fingolimod) to Treat Multiple Sclerosis in Pediatric Patients
May 11, 2018 -- The U.S. Food and Drug Administration today approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 11, 2018 Category: Drugs & Pharmacology Source Type: news

Fingolimod OK'd for Pediatric MS
(MedPage Today) -- First drug approved for multiple sclerosis in kids 10 and older (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 11, 2018 Category: American Health Source Type: news

FDA expands use of Novartis MS drug to pediatric patients
(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG's relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents. (Source: Reuters: Health)
Source: Reuters: Health - May 11, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients
FDA approves Gilenya (fingolimod) to treat multiple sclerosis MS in children age 10 and older. This is the first FDA approval of a drug to treat MS in pediatric patients (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 11, 2018 Category: American Health Source Type: news

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients
The U.S. Food and Drug Administration today approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in pediatric patients. (Source: World Pharma News)
Source: World Pharma News - May 11, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

La FDA advierte sobre casos de una infecci ó n cerebral infrecuente con el medicamento para la esclerosis m ú ltiple (EM) Gilenya (fingolimod) en dos pacientes que no hab í an tenido previamente exposici ó n a medicamentos inmunodepresores
[08-04-2015] La Administraci ó n de Alimentos y Medicamentos (FDA) de los Estados Unidos advierte sobre el reporte de un caso de leucoencefalopat í a multifocal progresiva (LPM) definitiva y de un caso de probable LPM en pacientes que tomaban Gilenya (fingolimod) por la esclerosis m ú ltiple (EM). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 6, 2018 Category: Drugs & Pharmacology Source Type: news

La FDA advierte sobre casos de una infecci ón cerebral infrecuente con el medicamento para la esclerosis múltiple (EM) Gilenya (fingolimod) en dos pacientes que no habían tenido previamente exposición a medicamentos inmunodepresores
[08-04-2015] La Administraci ón de Alimentos y Medicamentos (FDA) de los Estados Unidos advierte sobre el reporte de un caso de leucoencefalopatía multifocal progresiva (LPM) definitiva y de un caso de probable LPM en pacientes que tomaban Gilenya (fingolimod) por la esclerosis múltiple (EM). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 6, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs
[07-04-2015] The U.S. Food and Drug Administration is warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported in patients taking Gilenya (fingolimod) for multiple sclerosis (MS). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 6, 2018 Category: Drugs & Pharmacology Source Type: news

Rituximab Outperforms Other Drugs in RRMS Rituximab Outperforms Other Drugs in RRMS
In a new study, rituximab was superior to other drugs -- including fingolimod, natalizumab, and dimethyl fumarate -- in efficacy, safety, and tolerability in patients with relapsing-remitting MS.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 11, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Gilenya (Fingolimod Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 2, 2018 Category: Drugs & Pharmacology Source Type: news

Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Breakthrough Therapy designation can expedite the development and review of therapies for serious conditions(1) In a pivotal Phase III study, oral fingolimod significantly reduced relapses by 82% in a pediatric patient population vs. interferon beta-1a ... Biopharmaceuticals, Neurology, FDA Novartis, Gilenya, Fingolimod, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 18, 2017 Category: Pharmaceuticals Source Type: news

New daily tablet offers hope to MS youngsters
Experts have hailed the results of a trial of the drug Gilenya as ‘some of the most promising ever seen’ following a study of 215 children aged between ten and 17 from across the globe. (Source: the Mail online | Health)
Source: the Mail online | Health - November 11, 2017 Category: Consumer Health News Source Type: news

Impressive Results With Fingolimod in Pediatric MS Impressive Results With Fingolimod in Pediatric MS
In the first randomized trial in pediatric multiple sclerosis, fingolimod was associated with sizable reductions in relapse rate, new MRI lesions, brain atrophy, and disability progression compared with interferon beta.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 1, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Oral Drug Beats Interferon in First Pediatric MS Trial
(MedPage Today) -- Fingolimod cut relapses, brain shrinkage but with more adverse events (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - October 29, 2017 Category: General Medicine Source Type: news

Cardiac Effects of Fingolimod in MS Reversible Cardiac Effects of Fingolimod in MS Reversible
Fingolimod, used to treat multiple sclerosis, dampens cardiac autonomic modulation at rest and during challenges, but this effect appears to be reversible after discontinuation of the drug, a study shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 25, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Pharma ’s social contract: time for everyone to join in
When a scandal occurs in pharma, the whole industry is tarred by the same brush. We ’re still suffering the ill effects of Martin Shkreli’s 5000%overnight price increase of a life-saving anti-parastic, from way back in 2015.Pharma ’s trust problemBrent Saunders, Chairman& CEO of Allergan,sees this as part and parcel of doing business in this industry. Pricing will always be controversial within healthcare, because choosing between two sets of health outcomes is fundamentally different from choosing between two different brands of an electric toaster. The problem is: this reality isn ’t wide...
Source: EyeForPharma - September 6, 2017 Category: Pharmaceuticals Authors: Paul Simms Source Type: news

Pharma ’s social contract: time for everyone to join in
When a scandal occurs in pharma, the whole industry is tarred by the same brush. We ’re still suffering the ill effects of Martin Shkreli’s 5000%overnight price increase of a life-saving anti-parastic, from way back in 2015.Pharma ’s trust problemBrent Saunders, Chairman& CEO of Allergan,sees this as part and parcel of doing business in this industry. Pricing will always be controversial within healthcare, because choosing between two sets of health outcomes is fundamentally different from choosing between two different brands of an electric toaster. The problem is: this reality isn ’t wide...
Source: EyeForPharma - September 6, 2017 Category: Pharmaceuticals Authors: Paul Simms Source Type: news

MS Drug Works in Kids
(MedPage Today) -- Top-line results suggest good safety profile for fingolimod in pediatric MS (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - September 5, 2017 Category: Neurology Source Type: news

Bone Health Drug Inhibits Mesothelioma Tumor Growth
A drug used to treat bone disease and high blood calcium levels may carry benefits as part of a combination treatment for malignant pleural mesothelioma, a recent study concluded. Researchers at the University of Alabama at Birmingham Comprehensive Cancer Center conducted a pilot study testing the effects of zoledronic acid — a bisphosphonate, or bone health drug, marketed as Reclast and Zometa — against a small group of patients with unresectable pleural mesothelioma. The study, published in the June edition of Lung Cancer: Targets and Therapy journal, was a follow-up to preclinical research showing zoledron...
Source: Asbestos and Mesothelioma News - July 20, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: bone disease treatment keytruda mesothelioma treatments Muhammad Omer Jamil reclast treating malignant pleural mesothelioma University of Alabama at Birmingham Comprehensive Cancer Center Zoledronic acid zometa Source Type: news

Fingolimod during pregnancy: Is it safe?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - June 7, 2017 Category: Consumer Health News Source Type: news

Multiple Sclerosis Drug Effectively Stops Mesothelioma Cells
Research from the University of Hawaii Cancer Center shows an immune suppression drug already used to treat multiple sclerosis could become an effective tool against malignant mesothelioma. The drug, fingolimod (FTY720), showed an ability to shrink mesothelioma tumors cells in the laboratory and in animal models without causing substantial side effects. Fingolimod, which is derived from the fungus isaria sinclairii, also is being studied for potential use with cervical, breast, lung and prostate cancers. This was the first study of its effectiveness with mesothelioma. The Journal of Translational Medicine published the res...
Source: Asbestos and Mesothelioma News - May 11, 2017 Category: Environmental Health Authors: Matt Mauney Tags: anti-cancer effect on mesothelioma cells Dr. Haining Yang fingolimod mesothelioma FTY720 immune suppression drugs isaria sinclairii Journal of Translational Medicine mesothelioma life expectancy multiple sclerosis drugs Repurposing drugs Source Type: news

Novartis real-world data at AAN confirms benefit of Gilenya ® on four key measures of disease activity in relapsing MS
Novartis today announced data from the Phase IV Multiple Sclerosis and clinical outcome and MRI in the US (MS-MRIUS) study, which confirmed the effectiveness of Gilenya® (fingolimod) in the real-world setting, supporting previous findings from Phase III trials[1],[2]. (Source: World Pharma News)
Source: World Pharma News - April 24, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Glenmark gets tentative nod from USFDA for Fingolimod capsules
"Glenmark Pharmaceuticals USA has been granted tentative approval by the USFDA for Fingolimod capsules, 0.5 mg, the generic version of Gilenya capsules." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 20, 2017 Category: Pharmaceuticals Source Type: news

Study sheds light on the biology of progressive form of multiple sclerosis
(Brigham and Women's Hospital) A research team led by scientists from Brigham and Women's Hospital has revealed how an FDA-approved drug works in the central nervous system in mice to suppress chronic inflammation. The drug, known as FTY720 (or Fingolimod) interferes with signals sent through sphingosine-1-phosphate receptors, and appears to reduce the pathogenic activities of astrocytes. The findings suggest the treatment may hold promise for a progressive and difficult-to-treat form of multiple sclerosis (MS) known as secondary progressive MS (SPMS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 8, 2017 Category: Global & Universal Source Type: news

How to empower your health and wellness customers
Vince Schaller, Managing Director, Schawk (Los Angeles) “Ask your doctor if it’s right for you.” That advice, familiar in the U.S. ever since direct-to-consumer pharmaceutical advertising became legal nearly 20 years ago, is still sound. But today, consumers are increasingly asking themselves, before they even schedule a doctor’s appointment, “What are the right choices for me?” Call it the increasing consumerism of health and wellness. Or, in the words of Kristin Hambelton, one of many CMOs who are bringing traditional marketing strategies to healthcare-oriented enterprises, call it the...
Source: Mass Device - February 2, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Blog Schawk Source Type: news

ANA: Fingolimod Modulates RAGE in MS (CME/CE)
(MedPage Today) -- Pro-inflammatory markers in the serum reduced as anti-inflammatory molecules increase (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - October 19, 2016 Category: Radiology Source Type: news

AMNOG and the German Reforms: What Will Change?
Germany is typically prioritized by the pharmaceutical industry: it remains a market with relatively high drug prices, offers extensive commercial opportunities and has an important position as an international reference country to 17 marketsi.The implementation of AMNOG in 2011 sought to reduce drug prices and relieve the healthcare budget, yet financial pressure remains, particularly from high-priced novel agents in Hepatitis C, and Oncology. As a result, in July 2016, the German Ministry of Health put forth a legislative proposal to reduce pharmaceutical spending and perceived exorbitant prices, as well as improve the A...
Source: EyeForPharma - October 3, 2016 Category: Pharmaceuticals Authors: Preeti Patel and Sophie Schmitz Source Type: news

Alemtuzumab Comparison Data Show Some Surprises Alemtuzumab Comparison Data Show Some Surprises
New observational propensity-matched data on head-to-head comparisons of alemtuzumab with beta-interferon, fingolimod, and natalizumab show some unexpected findings.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 29, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Registry Data: Lemtrada More Effective than Competing MS Tx
(MedPage Today) -- Better than fingolimod or interferon; comparable to natalizumab (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - September 17, 2016 Category: Journals (General) Source Type: news

ECTRIMS: Rituximab Beats MS Drugs in Swedish Registry Study (CME/CE)
(MedPage Today) -- Finds survival advantage for rituximab over fingolimod and natalizumab (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - September 16, 2016 Category: Consumer Health News Source Type: news

Multiple Sclerosis May Rebound When Patients Stop Fingolimod Multiple Sclerosis May Rebound When Patients Stop Fingolimod
In this viewpoint, Dr Barclay discusses a series of five patients with rebound whose cases were consistent with others in the literature.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 19, 2016 Category: Neurology Tags: Neurology & Neurosurgery Viewpoint Source Type: news

Long-term Treatment With Fingolimod in MSLong-term Treatment With Fingolimod in MS
The results of this study support a continued beneficial effect of long-term fingolimod therapy in patients with relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 16, 2016 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Receptor variation influences fingolimod efficacy in mouse multiple sclerosis models
(JCI Journals) In this issue of JCI Insight, May Han of Stanford University and colleagues tested the hypothesis that genetic variants of the cell surface receptor that responds to S1P, S1PR1, may influence the efficacy of fingolimod. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 16, 2016 Category: Global & Universal Source Type: news

Real-world data favor dimethyl fumarate, fingolimod for MS
VANCOUVER – Dimethyl fumarate and fingolimod appear to have an edge over other disease-modifying therapies for multiple sclerosis (MS) in real-world practice, according to a comparative effectiveness... (Source: Clinical Neurology News)
Source: Clinical Neurology News - June 14, 2016 Category: Neurology Source Type: news

Real-world data favor dimethyl fumarate, fingolimod for MS
VANCOUVER – Dimethyl fumarate and fingolimod appear to have an edge over other disease-modifying therapies for multiple sclerosis (MS) in real-world practice, according to a comparative effectiveness... (Source: Family Practice News)
Source: Family Practice News - June 14, 2016 Category: Primary Care Source Type: news

Relapses Rebound in Patients With MS Stopping FingolimodRelapses Rebound in Patients With MS Stopping Fingolimod
As seen with natalizumab, a new study shows patients may experience rebound in relapses after stopping fingolimod. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Real risk of rebound syndrome following fingolimod cessation for MS
Rebound syndrome following cessation of fingolimod for multiple sclerosis occurs at a clinically relevant rate, shows research, prompting the need for further study on how best to sequence and discontinue such drugs. (Source: MedWire News)
Source: MedWire News - May 4, 2016 Category: Consumer Health News Tags: Multiple sclerosis Source Type: news

Patients May Rebound After Stopping Gilenya (CME/CE)
(MedPage Today) -- Severe rebound syndrome seen in 10% of cases after discontinuation (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - May 4, 2016 Category: Neurology Source Type: news

Fewer new lesions, side effects differentiate fingolimod from dimethyl fumarate
VANCOUVER – Multiple sclerosis patients discontinued treatment and relapsed earlier with dimethyl fumarate (Tecfidera) than with fingolimod (Gilenya), and had more gadolinium-enhancing lesions at 12... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 28, 2016 Category: Neurology Source Type: news

Rituximab outperforms fingolimod after natalizumab switch
Rituximab is more effective and better tolerated than fingolimod for patients with multiple sclerosis needing to switch from natalizumab due to JC-virus antibody positivity, research suggests. (Source: MedWire News)
Source: MedWire News - April 26, 2016 Category: Consumer Health News Tags: Multiple sclerosis Source Type: news

Rituximab is superior to fingolimod for certain patients with multiple sclerosis
A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab. The study included patients infected with JC virus, which is present in approximately 50% of the general population. While the virus generally causes no problems under normal circumstances, it can cause progressive multifocal leukoencephalopathy (PML), a serious demyelinating disease of the brain, in patients with immune deficiencies due to disease or immunosuppressant drugs. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 21, 2016 Category: Science Source Type: news

Fingolimod Easier to Swallow Than Dimethyl Fumarate?Fingolimod Easier to Swallow Than Dimethyl Fumarate?
Patients with multiple sclerosis are more likely to discontinue dimethyl fumarate than fingolimod after 2 years or less, largely because of tolerability issues, a real-world study has found. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 20, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Rituximab bests fingolimod in MS patients switching from natalizumab
For patients with relapsing-remitting multiple sclerosis (RRMS) switching to other therapies due to positive JC virus serology, treatment with rituximab resulted in a lower rate of clinical relapse... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 4, 2016 Category: Neurology Source Type: news